Samjin Pharmaceutical Selected for MOTIE's World-Class Plus Project

Advancing Innovative New Drugs and Developing Formulation and ADC Platform Technologies
Securing Four Years of R&D Support
"Full-Scale Global Technology Licensing of New Drugs"

Samjin Pharmaceutical announced on April 7 that it has been selected for the "World-Class Plus Project Support Program" by the Ministry of Trade, Industry and Energy. This program supports midsize companies with research and development (R&D), exports, financial services, and consulting. It aims to identify and foster companies with high growth potential in advanced industries such as biotechnology.

Sangjin Pharmaceutical Research Center exterior. Sangjin Pharmaceutical

Samjin Pharmaceutical was selected for its project titled "Advancement of Innovative New Drugs and Development of Antibody-Drug Conjugate (ADC) Platform Technology." The company's key pipeline, the immunology and inflammation treatment "SJN314," and its ADC platform were major areas of evaluation.

Through this project, Samjin Pharmaceutical plans to expand the indications for SJN314, establish its ADC platform, and advance its controlled-release formulation technology. SJN314 has completed preclinical studies and is preparing to enter clinical trials.

The company intends to leverage its ADC platform and formulation technologies to expand technology licensing and global commercialization in the future. Currently, Samjin Pharmaceutical has 16 new drug candidates in its pipeline and invests about 12% of its revenue in research and development.

A Samjin Pharmaceutical representative stated, "We plan to expand global technology licensing based on our core pipeline and platform technologies."

This content was produced with the assistance of AI translation services.